3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Status
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
4
Sponsor
Cancer Type
Breast
4
Head & Neck
2
Conditions
Breast Neoplasms
48
Neoplasm Metastasis
4
Hereditary Sensory and Autonomic Neuropathies
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Hyperglycemia
3
Multiple Endocrine Neoplasia Type 1
2
Advanced Breast Cancer
2
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pre-menopausal Breast Cancer
1
Pancreatic Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Hormone Receptor Positive Breast Carcinoma
1
Head and Neck Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
Genetic Diseases, Inborn
1
Gastrointestinal Neoplasms
1
Exanthema
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Ductal, Breast
1
Anatomic Stage III Breast Cancer AJCC v8
1
Advanced or Metastatic ER+ Breast Cancer
1
Advanced Solid Tumors With an Alteration of the PIK3CA Gene
1
Advanced HER2+Breast Cancer
1
Interventions
Fulvestrant
10
Letrozole
4
Alpelisib
4
ribociclib
3
palbociclib
3
Paclitaxel
2
NVP-BKM120
2
volagidemab
1
serabelisib
1
sapanisertib
1
olaparib
1
liposomal doxorubicin
1
gedatolisib
1
exemestane
1
dapagliflozin
1
capivasertib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
Secretin
1
STX-478
1
Metformin
1
Lomustine
1
Leuprolide
1
Irinotecan
1
Imlunestrant
1
Goserelin
1
Gemcitabine
1
Drug Therapy
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Alpelisib
×
Breast
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts
NCT03439046
2024-08-01
BioItaLEE
Novartis
Phase 3
Completed
287 enrolled
NCT03386162
2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2
Terminated
31 enrolled